Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
203 INR | +1.22% | +6.81% | -2.10% |
Jan. 18 | Nath Bio-Genes Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 | CI |
2023 | Transcript : Nath Bio-Genes Limited, Q2 2024 Earnings Call, Oct 17, 2023 |
Sales 2022 | 2.78B 33.42M | Sales 2023 | 3.01B 36.18M | Capitalization | 2.68B 32.23M |
---|---|---|---|---|---|
Net income 2022 | -673M -8.08M | Net income 2023 | 350M 4.2M | EV / Sales 2022 | 1.78 x |
Net Debt 2022 | 888M 10.66M | Net Debt 2023 | 672M 8.07M | EV / Sales 2023 | 1.11 x |
P/E ratio 2022 |
-6.02
x | P/E ratio 2023 |
7.67
x | Employees | 433 |
Yield 2022 |
0.94% | Yield 2023 |
1.42% | Free-Float | 50.8% |
Latest transcript on Nath Bio-Genes (India) Limited
1 day | +1.22% | ||
1 week | +6.81% | ||
Current month | +16.83% | ||
1 month | +13.12% | ||
3 months | -6.37% | ||
6 months | +9.97% | ||
Current year | -2.10% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 99-08-29 | |
Director of Finance/CFO | 63 | - | |
Compliance Officer | 30 | 18-07-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 64 | 99-08-29 | |
Director/Board Member | 60 | 12-10-09 | |
Director/Board Member | 42 | 15-03-29 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 203 | +1.22% | 1 320 |
24-04-23 | 200.6 | +1.19% | 2,542 |
24-04-22 | 198.2 | +3.74% | 5,788 |
24-04-19 | 191 | +0.53% | 3,671 |
24-04-18 | 190 | +1.09% | 4,899 |
Delayed Quote Bombay S.E., April 24, 2024 at 02:10 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
+11.73% | 3.25B | |
-95.58% | 1.61B | |
+0.53% | 1.62B | |
-0.80% | 1.26B | |
-1.03% | 1.24B | |
-11.15% | 1.19B | |
-10.58% | 1.22B | |
-.--% | 1.2B | |
0.00% | 1.19B |
- Stock Market
- Equities
- NATHBIOGEN Stock
- NATHBIOGEN Stock